ImmuPharma plc (IMM.L) LSE

5.30

+0.09(+1.73%)

Updated at September 08 08:12AM

Currency In GBp

ImmuPharma plc

Address

1 Bartholomew Close

London, EC1A 7BL

United Kingdom of Great Britain and Northern Ireland

Phone

44 20 7206 2650

Sector

Healthcare

Industry

Biotechnology

Employees

5

First IPO Date

October 28, 2003

Key Executives

NameTitlePayYear Born
Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBAChairman & Chief Executive Officer294,0001956
Dr. Timothy Gary Franklin M.B.A., Ph.D.Chief Operating Officer & Director252,0001964
Ms. Lara E. Sucheston-CampbellHead of Clinical & Medical Affairs0N/A
Ms. Ashley Louise Clarke A.C.A.Group Chief Financial Officer & Company Secretary0N/A
Dr. Jean-Marie Geiger PharmD, MDHead of Clinical Development0N/A
Dr. Laura Mauran-Ambrosino Ph.D.Chief Scientific Officer of ImmuPharma Biotech0N/A

Description

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.